OBJECT: The object of this paper is to review the immunogenicity of bone morphogenetic proteins (BMPs) and to compare the results of the immunogenicity characterization and clinical consequences between recombinant human (rh)BMP-2 and recombinant human osteogenic protein-1 (rhOP-1/BMP-7). METHODS: The immunogenicity of therapeutic proteins and its clinical effects were reviewed. The characteristics of BMPs were also described in terms of immunogenicity. The methods and results of antibody detection in various clinical trials of rhBMP-2 and rhOP-1 were compared, including the most recent studies using a systematic characterization strategy with both a binding assay and bioassay. RESULTS: Similar to all recombinant human proteins, rhBMPs induce immune responses in a select subgroup of patients. Adverse effects from this response in these patients, however, have not been reported with antibody formation to either rhBMP-2 or rhOP-1. Overall, the incidence of antibody formation was slightly higher in rhOP-1 trials than in rhBMP-2 trials. CONCLUSIONS: Although they occur in a subgroup of patients, the immune responses against rhBMPs have no correlation with any clinical outcome or safety parameter. Clinicians, however, must be aware of the potential complications caused by the immunogenicity of BMPs until more studies clearly elucidate their safety.
OBJECT: The object of this paper is to review the immunogenicity of bone morphogenetic proteins (BMPs) and to compare the results of the immunogenicity characterization and clinical consequences between recombinant human (rh)BMP-2 and recombinant humanosteogenic protein-1 (rhOP-1/BMP-7). METHODS: The immunogenicity of therapeutic proteins and its clinical effects were reviewed. The characteristics of BMPs were also described in terms of immunogenicity. The methods and results of antibody detection in various clinical trials of rhBMP-2 and rhOP-1 were compared, including the most recent studies using a systematic characterization strategy with both a binding assay and bioassay. RESULTS: Similar to all recombinant human proteins, rhBMPs induce immune responses in a select subgroup of patients. Adverse effects from this response in these patients, however, have not been reported with antibody formation to either rhBMP-2 or rhOP-1. Overall, the incidence of antibody formation was slightly higher in rhOP-1 trials than in rhBMP-2 trials. CONCLUSIONS: Although they occur in a subgroup of patients, the immune responses against rhBMPs have no correlation with any clinical outcome or safety parameter. Clinicians, however, must be aware of the potential complications caused by the immunogenicity of BMPs until more studies clearly elucidate their safety.
Authors: Soonchul Lee; Jia Shen; Hsin Chuan Pan; Swati Shrestha; Greg Asatrian; Alan Nguyen; Carolyn Meyers; Vi Nguyen; Min Lee; Chia Soo; Kang Ting; Aaron W James Journal: Tissue Eng Part A Date: 2016-10-18 Impact factor: 3.845
Authors: Georg A Feichtinger; Anna T Hofmann; Paul Slezak; Sebastian Schuetzenberger; Martin Kaipel; Ernst Schwartz; Anne Neef; Nikolitsa Nomikou; Thomas Nau; Martijn van Griensven; Anthony P McHale; Heinz Redl Journal: Hum Gene Ther Methods Date: 2013-11-27 Impact factor: 2.396
Authors: Emily K Cushnie; Bret D Ulery; Stephen J Nelson; Meng Deng; Swaminathan Sethuraman; Stephen B Doty; Kevin W H Lo; Yusuf M Khan; Cato T Laurencin Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240